All In Biotech

Drug Trial Radar · NCT05278338

Efficacy and Safety of JMT103 in the Treatment of Postmenopausal Women With Osteoporosis

A Multicenter, Randomized, Double-blind, Placebo/Positive-controlled Phase II Study to Evaluate the Efficacy and Safety of JMT103 in Postmenopausal Women With Osteoporosis

Last checked: Nov 19, 2026Latest source record: Jul 18, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

200

Planned (sponsor's estimate)

Start

Apr 21, 2022

Primary completion

Dec 31, 2023

Study completion Mar 31, 2024

Sponsor

Lead sponsor
Shanghai JMT-Bio Inc.Industry
Sponsor type
Industry
First posted
Mar 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 50 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to evaluate the efficacy and safety of JMT103 in the treatment of postmenopausal women with osteoporosis.

Conditions

  • Postmenopausal Osteoporosis

Interventions

  • JMT103Drug

    subcutaneous injection, once every 6 months (Q6M), with a total of 2 administrations

  • DenosumabDrug

    subcutaneous injection, once every 6 months (Q6M), with a total of 2 administrations

  • PlaceboDrug

    subcutaneous injection, once every 6 months (Q6M), with a total of 2 administrations

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change rate of lumbar bone mineral density (BMD) from baseline at 12 months of JMT103 treatmentTime frame: Baseline and 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Second Hospital of Jilin University

    Changchun, Jilin, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.